[225Ac]Ac-ETN029

[225Ac]Ac-ETN029 is a **therapeutic radiopharmaceutical** composed of the alpha-emitting radioisotope actinium-225 conjugated to the targeting molecule ETN029, which modulates **Delta-like protein 3 (DLL3)**. This drug delivers targeted ionizing radiation to DLL3-expressing tumor cells, inducing cell death primarily via DNA double-strand breaks caused by alpha particle emissions. It is under development for treatment of advanced, DLL3-positive solid tumors—including small cell lung cancer, large cell neuroendocrine carcinoma, prostate neuroendocrine carcinoma, and gastroenteropancreatic neuroendocrine tumors. [225Ac]Ac-ETN029 is currently being investigated in Phase I clinical studies to assess its safety, tolerability, dosimetry, and preliminary efficacy in adult patients with locally advanced or metastatic DLL3-positive cancers[1][3][5][7][8][10].

Other names

[225Ac]Ac-ETN029225Ac ETN 029Actinium-225 ETN 029Actinium225 ETN 029Actinium 225 ETN 029225Ac-ETN-029